Mao J et al. |
Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound. |
2017 |
Pharm. Res. |
pmid:28815392
|
Gjestad C et al. |
4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. |
2017 |
Br J Clin Pharmacol |
pmid:28585378
|
Jiang X et al. |
An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. |
2017 |
Clin Pharmacol Drug Dev |
pmid:27138546
|
Wollmann BM et al. |
4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. |
2017 |
Clin Transl Sci |
pmid:27991741
|
Hole K et al. |
Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. |
2017 |
Eur. J. Clin. Pharmacol. |
pmid:27975131
|
Oh J et al. |
Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). |
2017 |
Diabetes Obes Metab |
pmid:27761990
|
Mao J et al. |
Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. |
2017 |
Drug Metab. Rev. |
pmid:27718639
|
Størset E et al. |
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28146606
|
Vanhove T et al. |
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28603840
|
Björkhem-Bergman L et al. |
Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations. |
2016 |
Basic Clin. Pharmacol. Toxicol. |
pmid:26617265
|
Gjestad C et al. |
4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? |
2016 |
Br J Clin Pharmacol |
pmid:26574235
|
Woolsey SJ et al. |
Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. |
2016 |
Basic Clin. Pharmacol. Toxicol. |
pmid:26399557
|
Pataj Z et al. |
Quantification of oxysterols in human plasma and red blood cells by liquid chromatography high-resolution tandem mass spectrometry. |
2016 |
J Chromatogr A |
pmid:26607314
|
Hasan M et al. |
Rapid LC-MS/MS method for the determination of 4-hydroxycholesterol/cholesterol ratio in serum as endogenous biomarker for CYP3A activity in human and foals. |
2016 |
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. |
pmid:27565568
|
Vanhove T et al. |
Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. |
2016 |
Br J Clin Pharmacol |
pmid:27501475
|
Aubry AF et al. |
Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity. |
2016 |
AAPS J |
pmid:27350147
|
Ishida T et al. |
Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain. |
2016 |
Drug Metab. Pharmacokinet. |
pmid:27236640
|
Xue YJ et al. |
Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. |
2016 |
Bioanalysis |
pmid:26805594
|
Hukkanen J et al. |
The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. |
2015 |
Br J Clin Pharmacol |
pmid:26095142
|
de Graan AJ et al. |
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. |
2015 |
Br J Clin Pharmacol |
pmid:26119961
|
Mannheimer B et al. |
No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. |
2015 |
PLoS ONE |
pmid:25835492
|
Naito T et al. |
CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. |
2015 |
Drug Metab. Pharmacokinet. |
pmid:26654672
|
Suzuki Y et al. |
Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. |
2014 |
Drug Metab. Dispos. |
pmid:24135442
|
Dutreix C et al. |
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. |
2014 |
Eur. J. Clin. Pharmacol. |
pmid:24839948
|
Kasichayanula S et al. |
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. |
2014 |
Br J Clin Pharmacol |
pmid:24837659
|
Nylén H et al. |
Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. |
2014 |
Basic Clin. Pharmacol. Toxicol. |
pmid:24655660
|
Li K et al. |
4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys. |
2014 |
Drug Metab. Dispos. |
pmid:24595680
|
Ngaimisi E et al. |
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. |
2014 |
J. Antimicrob. Chemother. |
pmid:25096076
|
Huang MQ et al. |
Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS. |
2014 |
Biomed. Chromatogr. |
pmid:24861746
|
Ikegami T et al. |
Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. |
2014 |
Biochem. Biophys. Res. Commun. |
pmid:24525121
|
Higashi T et al. |
LC/MS/MS of steroids having vicinal diol as electrospray-active boronates. |
2013 |
Chem. Pharm. Bull. |
pmid:23449202
|
Suzuki Y et al. |
Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. |
2013 |
J. Lipid Res. |
pmid:23833241
|
Nury T et al. |
Biological activities of the LXRα and β agonist, 4β-hydroxycholesterol, and of its isomer, 4α-hydroxycholesterol, on oligodendrocytes: effects on cell growth and viability, oxidative and inflammatory status. |
2013 |
Biochimie |
pmid:23220593
|
Björkhem-Bergman L et al. |
Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study. |
2013 |
Drug Metab. Dispos. |
pmid:23386704
|
Shin KH et al. |
Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. |
2013 |
Clin. Pharmacol. Ther. |
pmid:23784264
|
van de Merbel NC and de Vries R |
Aging of biological matrices and its effect on bioanalytical method performance. |
2013 |
Bioanalysis |
pmid:24066624
|
DeGorter MK et al. |
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. |
2013 |
Circ Cardiovasc Genet |
pmid:23876492
|
Xu Y et al. |
LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume. |
2013 |
J Pharm Biomed Anal |
pmid:23948760
|
Björkhem-Bergman L et al. |
Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. |
2013 |
Drug Metab. Dispos. |
pmid:23674608
|
Mårde Arrhén Y et al. |
A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction. |
2013 |
Br J Clin Pharmacol |
pmid:23116409
|
Goodenough AK et al. |
Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. |
2011 |
Chem. Res. Toxicol. |
pmid:21728364
|
Peters J et al. |
Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals. |
2011 |
Drug Metab. Dispos. |
pmid:21690264
|
Nylén H et al. |
Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol. |
2011 |
Eur. J. Clin. Pharmacol. |
pmid:21246351
|
van de Merbel NC et al. |
A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma. |
2011 |
J Pharm Biomed Anal |
pmid:21507593
|
Gebeyehu E et al. |
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. |
2011 |
Pharmacogenomics J. |
pmid:20231858
|
Diczfalusy U et al. |
4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. |
2011 |
Br J Clin Pharmacol |
pmid:21219398
|
Yang Z and Rodrigues AD |
Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? |
2010 |
J Clin Pharmacol |
pmid:20197489
|
Lütjohann D et al. |
4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. |
2009 |
Int J Clin Pharmacol Ther |
pmid:19954708
|
Honda A et al. |
Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. |
2009 |
J. Lipid Res. |
pmid:18815436
|
Allmyr M et al. |
Human exposure to triclosan via toothpaste does not change CYP3A4 activity or plasma concentrations of thyroid hormones. |
2009 |
Basic Clin. Pharmacol. Toxicol. |
pmid:19686543
|